Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Theravance Biopharma (TBPH) over the last 13 years, with Q2 2025 value amounting to $50.2 million.

  • Theravance Biopharma's Shares Outstanding (Weighted Average) rose 293.35% to $50.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $50.2 million, marking a year-over-year increase of 293.35%. This contributed to the annual value of $48.8 million for FY2024, which is 1167.39% down from last year.
  • Per Theravance Biopharma's latest filing, its Shares Outstanding (Weighted Average) stood at $50.2 million for Q2 2025, which was up 293.35% from $49.7 million recorded in Q1 2025.
  • In the past 5 years, Theravance Biopharma's Shares Outstanding (Weighted Average) ranged from a high of $76.3 million in Q2 2022 and a low of $48.3 million during Q1 2024
  • Its 5-year average for Shares Outstanding (Weighted Average) is $61.3 million, with a median of $61.4 million in 2023.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 1667.47% in 2022, then plummeted by 2485.09% in 2023.
  • Theravance Biopharma's Shares Outstanding (Weighted Average) (Quarter) stood at $69.5 million in 2021, then grew by 5.95% to $73.6 million in 2022, then decreased by 24.85% to $55.3 million in 2023, then decreased by 11.67% to $48.8 million in 2024, then rose by 2.72% to $50.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $50.2 million for Q2 2025, versus $49.7 million for Q1 2025 and $48.8 million for Q4 2024.